MX2010012421A - 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1. - Google Patents

5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.

Info

Publication number
MX2010012421A
MX2010012421A MX2010012421A MX2010012421A MX2010012421A MX 2010012421 A MX2010012421 A MX 2010012421A MX 2010012421 A MX2010012421 A MX 2010012421A MX 2010012421 A MX2010012421 A MX 2010012421A MX 2010012421 A MX2010012421 A MX 2010012421A
Authority
MX
Mexico
Prior art keywords
alkyl
prolinam
methylpropanoylmethyl
ide
pyridinyl
Prior art date
Application number
MX2010012421A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Agostino Marasco
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of MX2010012421A publication Critical patent/MX2010012421A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Esta invención provee un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo, en donde R es alquilo de C1-4 (ver fórmula (I)) útil en el tratamiento de enfermedades y condiciones para las cuales el antagonismo del receptor NK1 es benéfico.
MX2010012421A 2008-05-14 2009-05-12 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1. MX2010012421A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0808747.0A GB0808747D0 (en) 2008-05-14 2008-05-14 Novel compounds
PCT/EP2009/055700 WO2009138393A1 (en) 2008-05-14 2009-05-12 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2010012421A true MX2010012421A (es) 2011-03-25

Family

ID=39571329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012421A MX2010012421A (es) 2008-05-14 2009-05-12 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.

Country Status (22)

Country Link
US (4) US8344005B2 (es)
EP (1) EP2300452B1 (es)
JP (1) JP5465716B2 (es)
KR (1) KR101567116B1 (es)
CN (1) CN102105458B (es)
AR (1) AR071721A1 (es)
AU (1) AU2009248102B8 (es)
BR (1) BRPI0911990B1 (es)
CA (1) CA2724219C (es)
CL (1) CL2009001146A1 (es)
DK (1) DK2300452T3 (es)
EA (1) EA019037B1 (es)
ES (1) ES2446866T3 (es)
GB (1) GB0808747D0 (es)
IL (1) IL209197A (es)
MX (1) MX2010012421A (es)
PE (1) PE20091847A1 (es)
PL (1) PL2300452T3 (es)
TW (1) TWI444376B (es)
UY (1) UY31824A (es)
WO (1) WO2009138393A1 (es)
ZA (1) ZA201007904B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
EP3067349B1 (en) 2013-11-08 2018-02-28 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
JP6609253B2 (ja) * 2014-08-06 2019-11-20 キッセイ薬品工業株式会社 シアノチオフェン誘導体
WO2018197638A1 (en) 2017-04-27 2018-11-01 Nerre Therapeutics Limited Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide
EP4096508A4 (en) * 2020-01-30 2024-03-27 Javed, Mohammad COMBINATION THERAPIES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
US11872222B2 (en) 2020-06-02 2024-01-16 Nerre Therapeutics Limited Uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
KR100514236B1 (ko) 1999-02-24 2005-09-13 에프. 호프만-라 로슈 아게 페닐 유도체 및 피리디닐 유도체
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
SI1303490T1 (sl) 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
ATE323531T1 (de) 2001-04-23 2006-05-15 Hoffmann La Roche Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
DE602006021323D1 (de) * 2005-09-09 2011-05-26 Glaxosmithkline Llc Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators

Also Published As

Publication number Publication date
EA019037B1 (ru) 2013-12-30
PL2300452T3 (pl) 2014-04-30
US8344005B2 (en) 2013-01-01
US8822504B2 (en) 2014-09-02
JP5465716B2 (ja) 2014-04-09
GB0808747D0 (en) 2008-06-18
US20110060015A1 (en) 2011-03-10
AR071721A1 (es) 2010-07-07
EA201071299A1 (ru) 2011-06-30
CA2724219A1 (en) 2009-11-19
CN102105458B (zh) 2013-06-12
BRPI0911990B1 (pt) 2021-07-13
CN102105458A (zh) 2011-06-22
TWI444376B (zh) 2014-07-11
KR20110017384A (ko) 2011-02-21
US20130143931A1 (en) 2013-06-06
DK2300452T3 (da) 2014-02-17
EP2300452B1 (en) 2013-11-20
WO2009138393A1 (en) 2009-11-19
BRPI0911990A2 (pt) 2020-08-18
PE20091847A1 (es) 2010-01-09
US20140249188A1 (en) 2014-09-04
ES2446866T3 (es) 2014-03-10
KR101567116B1 (ko) 2015-11-06
AU2009248102B8 (en) 2012-07-26
AU2009248102B2 (en) 2012-06-28
UY31824A (es) 2009-11-10
CL2009001146A1 (es) 2010-09-24
US20090286836A1 (en) 2009-11-19
JP2011520834A (ja) 2011-07-21
US9006271B2 (en) 2015-04-14
TW201006813A (en) 2010-02-16
CA2724219C (en) 2016-04-05
AU2009248102A1 (en) 2009-11-19
EP2300452A1 (en) 2011-03-30
IL209197A0 (en) 2011-01-31
ZA201007904B (en) 2011-11-30
IL209197A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
MX2010012421A (es) 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
NZ591172A (en) Compounds for the treatment of hepatitis c
JO2885B1 (en) Protein kinase inhibitors
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
EA201000050A1 (ru) Замещенные бициклолактамные соединения
GEP201706728B (en) Noxious organism control agent
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
MX2008016423A (es) Arilamidas sustituidas con tetrazol.
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
WO2007026920A3 (en) Amide derivatives as rock inhibitors
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
PE20080319A1 (es) Dihidrotienopirimidinas como agentes inhibidores de pde-4
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
MY151295A (en) Pyrimidyl indoline compound
HK1138262A1 (en) Novel phosphodiesterase inhibitors
TW200740827A (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
SE0301232D0 (sv) Novel use
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights